Safety and efficacy of Pulmonary physiotherapy in hospitalized patients with severe COVID-19 pneumonia (PPTCOVID Study): A prospective, randomised, single-blind, controlled trial

4

Short Title: "Safety and efficacy of Pulmonary physiotherapy in patients with severe COVID 19"

7

8 Mohammad Javaherian^{1,2}, Azadeh Shadmehr¹, Abbasali Keshtkar³, Mohammad-Taghi Beigmohammadi⁴, Narges

9 Dabbaghipour¹, Aabis Syed¹, Behrouz Attarbashi Moghadam^{1*}

¹ Department of Physiotherapy, School of Rehabilitation, Tehran University of Medical Sciences, Tehran, Iran.

² Liver Transplantation Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical

12 Sciences, Tehran, Iran.

13 3 Department of Health Sciences Education Development, School of Public Health, Tehran University of Medical

14 Sciences and Health Services, Tehran, Iran.

⁴ Department of Anesthesiology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences,

16 Tehran, Iran.

17 * Corresponding author

18 Email: Attarbashi@tums.ac.ir

20 Abstract

21 Background: Pulmonary physiotherapy (PPT) is an important treatment in the management of

22 patients with different types of pulmonary disorders. We aimed to evaluate safety and efficacy of

23 PPT in hospitalized patients with severe COVID-19 pneumonia.

24 Methods: In this randomised, single-blind, controlled trial, we enrolled hospitalized, nonintubated patients (18 to 75 years with oxygen saturation (Spo2) in free-air breathing $\leq 90\%$) with 25 COVID-19 pneumonia at a referral hospital. Participants were randomly assigned (1:1) to 26 receive PPT (six sessions PPT with breathing exercises and airway clearance techniques) or 27 basic care. The primary outcomes were venous blood O2 (pO2) and CO2 (pCO2) pressures, 28 29 Spo2, and three-minute walking test (3MWT) that were assessed before and end of sixth session. Secondary outcomes included level of dyspnea, venous blood PH, one-month mortality, three-30 31 month mortality and short form-36 (SF-36) after one and three months. The assessor was blinded 32 to the assignment. This trial is registered with ClinicalTrials.gov (NCT04357340).

Findings: In April-May 2020, 40 participants were randomly assigned to PPT or basic care 33 groups. While at the end of intervention, pO2 (adjusted mean difference to baseline measure 34 35 (AMD) 6.43 mmHg [95%CI 2.8, 10.07], P<0.01), Spo2 (AMD 4.43% [95%CI 2.04, 6.83], 36 P=0.0011), and 3MTW (AMD 91.44 m [95%CI 68.88, 113.99], P<0.01) were higher in PPT group and basic care group, pCO2 was not improved (AMD -2.1 mmHg [95%CI-6.36, 2.21], 37 P=0.33). Mortality rate was 20% (OR adjusted to baseline Spo2 .19 [95%CI .03, 1.30], P=.09) 38 and 25% (OR adjusted to baseline Spo2 .16 [95%CI .26, 1.05], P=.056) lower in the PPT group 39 at three-month at one-month and three-month, respectively. There were no significant 40 41 differences in most SF-36 domains scores after one and three months. No serious adverse event was observed during PPT sessions. 42

43 Conclusion: Early PPT can be considered a safe and effective therapeutic choice for patients with44 severe COVID-19.

45 Keywords: Physiotherapy, Pulmonary, Coronavirus Disease 2019, COVID-19, Rehabilitation

47 Introduction

- In late December 2019, the coronavirus infection pneumonia epidemic broke out and rapidly
- 49 spread worldwide [1]. Now almost all countries are challenging with coronavirus disease 2019
- 50 (COVID-19). Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) not only
- 51 induced more than 194 million definite COVID-19 cases and four million mortality numbers yet,
- 52 but it also caused a challenge in healthcare systems and the economic conditions of most
- 53 countries [2].
- 54 Patients with COVID-19 can present influenza-like signs and symptoms like fever (89%), cough
- 55 (68%), fatigue (38%), excessive pulmonary secretion (EPS) or sputum (34%), and breathlessness
- 56 (19%). The disease can appear asymptomatic or mild lower respiratory tract illness through
- 57 severe viral pneumonia with acute respiratory distress syndrome and even death [3]. Age> 60
- years, some underlying noncommunicable diseases like diabetes, hypertension, cardiovascular,
- kidney, and lung diseases, cerebrovascular diseases, immunosuppression, obesity, cancer, and
- even mental disorders are reported as risk factors associated with severe COVID-19 and
- 61 mortality [3].
- 62 Pulmonary physiotherapy (PPT) is a comprehensive therapeutic method that is aimed to improve
- 63 patient's respiratory symptoms, train effective cough, clear the airways, decrease symptoms of
- 64 dyspnea, re-expansion pf atelectatic lung, provide short-term improvement in lung-thorax
- 65 compliance, reduce the complications related to disease, minimize disability and finally improve
- the health-related quality of life (HRQOL) [4-6].
- ⁶⁷ Up to now, some studies with different designs and levels of evidence have been suggested PPT
- strategies for hospitalized patients with various stages of COVID-19 pneumonia [1, 4, 7-13].
- Almost all of their recommendations are based on expert opinion origin and reported data from
- 70 other viral pneumonia diseases such as influenza. These recommendations seem to have not
- sufficient experimental evidence in connection with COVID-19. The original studies have
- focused on rehabilitative or physical therapy processes after the severe stage of COVID-19 more
- than the acute stage to recovery muscle wasting, aerobic deconditioning, and possibly happened
- 74 disability due to prolonged immobility [14].
- Although some researchers and expert clinicians suggested that early PPT can be tailored in the
- condition of acute respiratory disease to prevent further muscular and aerobic systems
 - 3

77 deterioration, helping the therapeutic process, decrease hospitalization duration, and facilitate future recovery in patients with COVID-19 [4, 7, 11, 12], but there are some researchers 78 79 recommend that use of this treatment should be avoided for patients with COVID-19 especially in the severe or critical stage [3] except in some circumstance like the presence of a high amount 80 81 of EPS [9]. Most of these researchers believe that this treatment can be unsafe and ineffective for patients with acute COVID-19. Although some researchers reported that early PPT can be safe 82 83 and be associated with clinical improvement, prevention of potential complications due to underlying diseases and immobilisation, short length of stay and a decrease of mortality rate in 84 patients with critical diseases [15-18], but there is no high-quality randomised controlled trial 85 (RCT) evaluate the safety and efficacy of PPT in patients with severe COVID-19 after more than 86 18 months from SARS-Cov-2 spread in the world. This study was aimed to evaluate the safety 87 and efficacy of PPT on venous blood gas (VBG) analysis, peripheral blood oxygen saturation 88 (Spo2), three-minute walking test (3MWT), one-month and three-month HRQOL and mortality 89 90 rate in non-intubated patients with severe COVID-19 pneumonia. The result of this study can guide the clinicians and future researchers to include PPT into the protocol of severe COVID-19 91 management or not. It was hypothesized that participants receive PPT demonstrate improvement 92 in venous blood O2 & CO2 pressures (pO2 and pCO2, mmHg), Spo2, 3MWT, level of dyspnea, 93 one-month and three-month HRQOL, and decrease of one-month and three-month mortality 94 rates than participants in the control group. 95

96 Material and methods

97 Study design

This was a single-center, single-blind, prospective, two parallel-armed RCT comparing the 98 efficacy of six sessions PPT + basic care with basic care alone in hospitalized patients with 99 COVID-19 pneumonia. In April and May 2020, participants were recruited at COVID-19 100 101 intermediate care wards and intensive care units of Imam Khomeini Hospital Complex, Tehran, Iran. IKHC is known as the largest and one of the referral hospitals in Iran. Any related adverse 102 events during three days were monitored and recorded by a data safety monitoring committee. 103 104 Members of this committee were physicians of intermediate care wards and one medical ethics 105 specialist. They were asked to follow the procedure of applied interventions on patients by researchers and possible occurred adverse events which may be related to PPT. This trial was 106

- approved by the Ethical Committee of Tehran University of Medical Sciences
- 108 (IR TUMS.VCR.REC.1399.205). The authors had access to patients' medical records until
- 109 three months after recruitment.

110 **Participants**

- All participants were patients with COVID-19 pneumonia at a severe stage [3]. The inclusion
- 112 criteria were individuals: 1) 18 to 75 years old; 2) with confirmed COVID-19 by positive
- reaction real-time polymerase chain reaction test and presence of ground-glass opacification in
- their chest computed tomography scan; 3) severe stage of COVID-19 pneumonia indicated by
- 115 Spo2 < 90% after two-minute breathing the free air and respiratory rate > 30 breaths/min ;4) with
- full consciousness and oriented; 5) able to walk; 6) with O2 saturation < 90% after; 7) $100 \le$
- 117 $PaO2/FiO2 \le 200 \text{ mmHg}$, and 8) able to read and write in Persian. The exclusion criteria
- included 1) presence of any type of musculoskeletal disorder that prohibits the patient from
- 119 participating in the study; 2) history of intubation due to COVID-19 pneumonia; and 3) Any type
- 120 of obvious clinically mental or cognitive impairment. Potentially eligible participants were
- screened by review the admitted patient's medical records and a preliminary assessment. A
- signed informed consent form was obtained from all patients after explaining the study details to
- 123 them.
- 124 Participants who met one of the following conditions were withdrawn/dropped out from the
- study: 1) Unable to complete at least three sessions; 2) Dissatisfaction to continue to the study
- 126 for any reason; 3) Intubation or die during interventions; and; 5) Occurring unpredictable adverse
- 127 events during applying interventions.

128 **Randomisation and masking**

- 129 After consent was obtained, eligible individuals were assigned (1:1) to one of the treatment
- 130 groups using the blocked-balanced randomisation method [19] (block size: 4): 1) the
- experimental group (received six sessions PPT in addition to basic care interventions) or 2) the
- 132 control group (received basic care only). Randomization was done using an online system that
- 133 provides difference blocks order based on a random number (https://www.sealedenvelope.com).
- 134 The sealed envelopes were provided and stamped based on the order of randomised groups by a
- researcher (BAM) who had no role in the participants' assessment and treatment.
- 136 Physiotherapists allocated participants based on the order of the envelopes. The assessor and
- 137 statistical analysis team were masked to treatment allocation. The assessor had not also access to

138 patient's medical record. As PPT consists of some techniques that require the patient's

139 cooperation actively; therefore, participants masking was impossible.

140 **Procedures**

141 The process of enrollment, recruitment and the baseline assessment was performed in a same day. Medical history and demographic data were collected from participants after recruitment. 142 143 Patients underwent clinical evaluation at baseline, including VBG analysis, 3MWT, Spo2, and level of dyspnea. In order to VBG analysis, blood samples were taken from the upper extremity 144 145 peripheral veins after two-minutes of breathing free air in fowler's position by a nurse. Samples were immediately analyzed [20]. At this time, the patient's Spo2 was assessed using an index 146 147 finger pulse oximeter [21]. In the 3MWT, patients were asked to continue walking as their tolerance without portable oxygen receive using comfortable footwear. Heart rate and Spo2 were 148 149 monitored and the test was stopped in the condition of Spo2 < 80%, patient's inability to 150 continue, dyspnea, chest or limb pain [22]. Rated perceived exertion (RPE) during exercises was 151 evaluated using the Borg scale immediately after 3MWT [23]. The level of dyspnea was 152 evaluated using the visual analog scale [24]. To assess the level of dyspnea, the patient was 153 instructed that zero stands for no breath shortness and 10 shows maximum breath shortness. 154 Patient was asked to mark his/her feeling of dyspnea during the past 24 hours on the paper [25]. 155 The interventions were delivered over three days. The number of days and sessions for applying the intervention was determined after analyzing the mean of staying duration at intermediate care 156 157 wards, where patients with severe COVID-19 were admitted. Based on the result of primary 158 analysis, 78% of patients had admitted to intermediate care wards stayed for 3-4 days and they 159 were then transferred to other care wards (normal care wards or intensive care units). 160 Patients underwent a second assessment time at the end of day three (after the sixth session). Participants were also followed up to one month and three months to evaluate their survival rate 161 162 (using electronic medical records) and HRQOL using telephone assessment of short form-36 (SF-36) questionnaire. 163

164 **Basic care group:**

Participants in the basic care group received usual medical care, including medication based on
the national guideline of COVID-19 [26], oxygen therapy, possibly non-invasive ventilation
intervention, nursing care and monitoring, and etc. They also had one session of breathing
education with 40 minutes duration includes effective cough, if they felt EPS, diaphragmatic

breathing, and upper chest muscles relaxation. They also received an incentive spirometer and instructions on how to use it. They also were advised to walk as tolerate, even using a portable oxygen cylinder. This educational session was held in one of three days after the first assessment and before the second assessment.

173 **Pulmonary physiotherapy group:**

In addition to basic care interventions, patients allocated to the PPT group received a totally 6 174 175 PPT sessions for three consecutive days (twice daily: one session in the morning and one session 176 in the afternoon). PPT was started at the same day that patient was recruited. Patients received 177 two sessions of PPT in that day. Two expert pulmonary physiotherapists assessed patients immediately before every session to select the techniques based on their findings. It is reported 178 179 that about 34% of patients with COVID-19 pneumonia present signs and symptoms of EPS [3]. If the patient presented signs and symptoms of EPS presence like wheezing sound, and sputum 180 181 production, airway clearance techniques (ACTs) were applied. These techniques included active 182 cycle of breathing (ACBT), Autogenic Drainage, vibration, and postural drainage. If there was any contraindication for these techniques, only an effective cough technique was used. ACTs 183 were continued until successful secretions clearance based on therapists' assessment [27]. These 184 patients and whom without EPS signs and symptoms then received Inspiratory Hold Technique 185 186 (IHT) exercises. During these exercises, patients held their breath at the end of inspiration without using a Valsalva maneuver following by a relaxed exhalation. The physiotherapists 187 emphasized diaphragmatic breathing while performing the IHT by setting their palmar surface of 188 189 hand on patients' costal margin bilaterally to facilitate abdominal wall motion. Also, patients were educated to relax their upper chest muscles during exercises [27]. This technique was 190 performed ten times in three sets with 2 minutes rest between each set: 1) Set 1: three-second 191 192 hold, six-second rest; 2) Set 2: six-second hold; 12-second rest; 3) Set 3: 10-second hold, 20second rest. A summary of applied PPT techniques, contraindications, and criteria of holding the 193 interventions, is presented in Fig 1. 194

Fig 1. The protocol of applied pulmonary physiotherapy to patients with or without excessive pulmonary secretion.

Also, patients in this group underwent mild aerobic exercise by walking training after the third
session. Two criteria indicated the end of walking training: 1) O2 saturation < 80% or 2) 11 <

RPE < 13 based on the Borg's scale [28]. The maximum walking training time was determined
six minutes, and individuals could have rest intervals during this period.

201 **Outcome measures**

- 202 The primary outcomes were pO2 and pCO2 from VBG analysis. Arterial blood gas analysis was
- not selected to measure the O2 & CO2 pressures due to two reasons; first, patients in the
- intermediate care have not artery line and also blood sampling by syringe is a painful procedure;
- second, it has been shown that VBG analysis can be considered as an acceptable alternative for
- arterial blood gas analysis in patients with pulmonary diseases [20]. Other primary outcome
- 207 measures include Spo2 after 2 minutes breathing free air, and 3MWT distance.
- 208 The secondary outcomes included the level of dyspnea and RPE after 3MWT using Borg's scale
- [15], PH of VBG, one-month and three-month related mortality rates and, HRQOL by the
- 210 Persian version of SF-36 after one month and three months [29]. As recruited patients had severe
- disease and could not respond to SF-36 questions, we did not assess their HRQOL at the
- 212 baseline.

213 Statistical analysis

- The sample size of this study was calculated based on minimal clinically importance difference
- (MCID) of Spo2. Considering standard deviation (SD) of 4.4%, MCID of 4%, two steps of
- 216 measurements (before and after), a correlation between measurements of .6, type I error of .05,
- and 80% power, a sample size of 13 participants per group was calculated. [30, 31]. As
- 218 participants were patients with severe COVID-19 pneumonia and the mortality rate seems to be
- high in this group, 50% loss to follow-up was estimated. Finally, 40 patients were considered as
- 220 a suitable sample size.
- 221 Stata version 13. (Stata, College, Statin, Texas) was used to analyze the data. We reported Means
- \pm SD and frequency counts (%) for continuous and categorical data, respectively. Data normality
- 223 was checked for all continuous variables using the P-P plot, Q-Q plot, and Shapiro-Wilk test.
- 224 Analysis of variance and covariance (ANOVA/ANCOVA) was used to determine the differences
- of all continuous data, with the baseline score included as a covariate (one factor, one covariate)
- [32, 33]. Also, we selected blood Spo2 as another covariate (one factor, two covariates) due to
- two reasons: 1) Spo2 can be considered one of the important factors to predict mortality in
- hospitalized patients with COVID-19 pneumonia [31, 33]. Second, the MD of Spo2 between
- groups was more than $.2 \times SD$ of all participants' Spo2 [34]. The point estimates of effects were

- reported as MD with a 95% confidence interval (CI), standardized mean difference (SMD) with
- 231 95% CI analyzed by Cohen's d. We considered .2 .49, .5 .79, .8 1.19 and, > 1.2 valuables as
- small, moderate, large, and very large SMD effects, respectively. To compare three analysis
- models and the effectiveness of cofounder/covariable impact on the results, partial eta2 effect
- size was provided. Change of partial $eta^2 > 10\%$ between three analysis models was considered
- important. In the analysis of categorical data, intention-to-treat (ITT) analysis was utilized for all
- 236 categorical data.
- 237 The number needed to treat (NNT) was calculated using an online calculator for all measures
- [35]. This system transforms Cohen's d into NNT and therefore is difficult to interpret. Alpha \leq
- 239 .05 was considered a statistically significant level.
- 240 The study was registered at <u>www.clinicaltrials.gov</u> (ClinicalTrials.gov Identifier NCT04357340).
- 241 The registration process was completed some days after recruitment and before primary
- completion. The reason why recruitment was not started after registration was our particular
- situation at that time in our center related to the pre-planned timetable for studies related to the
- 244 COVID that the Research deputy of the hospital had determined. Therefore, we had to start study
- before having the registration number. The authors confirm that all ongoing and related trials for
- this drug/intervention are registered.

247 Modifications to the study protocol

- Level of dyspnea, RPE after the 3MWT, and PH from VBG analysis were considered as secondary outcome measurements, while they were identified as primary outcomes in registration. History of intubation due to COVID-19 pneumonia was considered as another exclusion criteria. Also, the survival rate and HRQOL assessment were evaluated after three months as second follow-up. The permissions for these amendments were obtained from the
- ethical committee. The details and reason for the protocol modifications are presented in S1.

254 Role of the funding source

- 255 This study was funded by the Tehran University of Medical Sciences. The founder of the study
- had no role in study design, data collection, analysis, interpretation, or writing the manuscript.
- 257 The corresponding author had full access to all the data in the study and is responsible for
- 258 publishing the results.

259 **Results**

- In April and May 2020, 255 patients were screened, of whom 40 (age: 55.5 ± 13.7) met the
- criteria and were randomly allocated to PPT (n=20) or basic care (n=20) groups. From 20
- allocated patients to the PPT group, one (5%) was intubated at the end of the second day and
- died after nine days. The reason for intubation was suddenly hemodynamic instability, which
- was diagnosed due to pulmonary embolism. Two patients (10%) in the control group were
- intubated on the third day due to pneumonia progress and died three and eight days later. These
- 266 participants' baseline data were included in the statistical analysis. After one and three months,
- four participants (10%, two in PPT and two in basic care groups) and five participants (12.5%,
- two in the PPT group and three in the control group) declined to participate in a telephone-based
- assessment of SF-36. We found all participant's living status; therefore, no sample attrition
- 270 occurred. Accordingly, ITT and per-protocol were the same for categorical data analysis. The
- trial profile is presented in Fig 2.
- 272 Fig 2. Trial profile.
- 273 The demographic and clinical characteristics of all participants are presented in Table 1.

Table 1. Demographics and clinical
characteristics of participants.

×	1				
	PPT group (n=20)	$\begin{array}{c} 274\\ \text{Basic care}\\ \text{group}\\ (n=20) 5\end{array}$			
Age (y) (Mean \pm SD)	54.4 ± 13.1	56.6 ± 14.4			
Sex					
Male, n (%) Female, n (%)	13 (65) 7 (35)	12 (60) 8 (40)			
Height (cm) (Mean \pm SD)	172.4 ± 9.3	173.4 ± 7.4			
Weight (kg) (Mean \pm SD)	82.6 ± 11.8	79.8 ± 19.3			
BMI (kg/m ²) (Mean \pm SD)	27.9 ± 4.3	26.2 ± 4.4			
Comorbidity, n (%)					
Any comorbidity, n (%)	10 (50)	9 (45)			
Diabetes mellitus, n (%)	5 (25)	2 (10)			
Cardiovascular disease, n (%)	4 (20)	4 (20)			
Pulmonary dysfunction (s), n (%)	1 (5)	1 (5)			
Renal failure, n (%)	0 (0)	2 (10)			
Others, n (%)	2 (10)	1 (5)			
Smoker, n (%)	3 (15)	4 (20)			
Occupational environmental exposure, n (%) ^a	2 (10)	3 (15)			
Routine Ventilation Type ^b					
Nasal, n (%)	2 (10)	3 (15)			
Face mask, n (%)	4 (20)	3 (15)			
Partial rebreathing mask, n (%)	13 (65)	12 (60)			
CPAP, n (%)	1 (5)	2 (10)			
Duration of Stay before enrolment (Mean \pm SD)	10.1 ± 11.5	9.5 ± 6.8			
Baseline O□ saturation (%, Mean ± SD)	83.4 ± 4.9	84.4 ± 3.9			
PPT: Pulmonary physiotherapy; SD: Standard deviation; BMI: Body mass index; CPAP: Continuous positive airway					
pressure ^a defines as patient's exposure to some materials like					

^a defines as patient's exposure to some materials like asbestos, arsenic, coal, etc., which can cause pulmonary disease.

^b Defined as prescribed ventilation type for patient by physician which should be used most of the time.

* All of the participant's characteristics are statistically similar between groups based on t-test and chi-square test.

276 In the crude model analysis, the mean pO2 (MD: 5.81 [1.51, 10.11], SDM: .9 [.21, 1.57]), Spo2

277 (MD: 3.99 [1.5, 6.47], SMD: 1.07 [.37, 1.76]), 3MWT distance (MD: 81.82 [47.93, 115.7],

- 278 SMD: 1.61 [.86, 2.35]), level of dyspnea (MD: -2.08 [-2.96, -1.19], SMD: -1.57 [-2.31, -.82]),
- 279 RPE after walking (MD: -4.04 [-5.76, -2.32], SMD: -1.56 [-2.3, -.82]) and, PH (MD: .06, [.01,
- .12], SMD: .74 [.71, 1.41]) were statistically significant different between groups in all analysis
- models ($P \le .03$, Table 2). Also, pCO2 was insignificantly decreased (MD: -1.68 [-6.8, 3.44],
- SMD: -.22 [-.43, .86]). In the ANCOVA with adjusting each variable to its baseline measure, the
- partial eta² were improved > 10%. Considering baseline Spo2, partial eta² were slightly reduced
- in all variables except level of dyspnea which was slightly increased (Table 2).

Clinical	PPT group (n =19)		Basic care group (n =18)					Partial
Outcome	Baseline [*]	After [*]	<u>(n =</u> Baseline [*]	After [*]	F (P value) **	MD [95 % CI]	SMD [95 % CI]	eta ²
					7.5 (< .01) ^a	5.81 [1.51, 10.11]	.9 [.21, 1.57]	.177
pO2 (mmHg)	29.4 ± 5.3	38.7 ± 5.3	30.6 ± 8.2	32.9 ± 7.5	13 (< .01) ^b	6.43 [2.8, 10.07]	1.18 [.48, 1.88]	.276
(mmrg)	5.5	5.5	0.2	7.5	12.04 (< .01) ^c	6.39 [2.64, 10.14]	1.15 [.45, 1.84]	.267
					.44 (.51) ^a	-1.68 [-6.8, 3.44]	22 [43, .86]	.012
pCO2 (mmHg)	40 ± 7.3	37 ± 7.2	39.3 ± 8	38.6 ± 8.1	.97 (.33) ^b	-2.1 [-6.36, 2.21]	32 [97, .33]	.027
(mmrg)		7.2		0.1	.62 (.44) ^c	-1.7 [-6.01, 2.65]	26 [91, 39]	.018
Spo2	83.4 ±	90.21 ±	84.4 ±	86.2 ± 4	10.63 (< .01) ^a	3.99 [1.5, 6.47]	1.07 [.37, 1.76]	.233
(Free air) (%)	4.9	3.4	3.9	80.2 ± 4	14.2 (< .01) ^b	4.43 [2.04, 6.83]	1.25 [.53, 1.95]	.294
					24.03 (< .01) ^a	81.82 [47.93, 115.7]	1.61 [.86, 2.35]	.407
Distance of 3MWT (m)	46 ± 24.3	149.1 ± 63	50 ± 24.4	67.3 ± 33.1	67.9 (< .01) ^b	91.44 [68.88, 113.99]	2.72 [1.81, 3.62]	.666
					64.33 (< .01) ^c	91.62 [68.38, 114.86]	2.67 [1.76, 3.55]	.661
					22.89 (< .01) ^a	-2.08 [-2.96, -1.19]	-1.57 [-2.31,82]	.395
Level of Dyspnea	5 ± 2	1.54 ± 1.2	5.19 ± 1.4	3.6 ± 1.5	38.44 (<.01) ^b	-1.98 [-2.63, -1.33]	-2.04 [-2.83, - 1.23]	.531
					36.54 (< .01) ^c	-1.99 [-2.66, -1.32]	-2 [-2.79, -1.2]	.525
					22.6 (< .01) ^a	-4.04 [-5.76, -2.32]	-1.56 [-2.3,82]	.393
RPE after Walking	16.2 ± 1.6	10.8 ± 3	17 ± 1.3	14.8 ± 2	18 (< .01) ^b	-3.46 [-5.12, -1.8]	-1.42 [-2.14,69]	.346
			15.67 (< .01) ^c	-3.32 [-5.03, -1.62]	-1.34 [-2.05,62]	.322		
				5.11 (.03) ^a	.06 [.01, .12]	.74 [.71, 1.41]	.127	
PH from VBG		7.5 ± .07	7.44 ± .06	$7.43\pm.1$	8.38 (< .01) ^b	.08 [.02, .13]	.96 [.27, 1.63]	.198
					7.31 (< .01) ^c	.07 [.02, .13]	.9 [.22, 1.57]	.181

PPT: Pulmonary physiotherapy; pO2: Mixed venous O_2 pressure; pCO2: Mixed venous CO_2 pressure; Spo2: Oxygen saturation; 3MWT: Three-minute walk test; RPE: Rating of perceived exertion; VBG: Venous blood gas; MD: Mean difference; CI: Confidence interval; SMD: Standardized mean difference (based on Cohen's d test), ANOVA: Analysis of variance, ANCOVA: Analysis of covariance. *Expressed as mean \pm standard deviation. The baseline and after values present the result of participants' assessment before and after three days, respectively.

** Analyzed using ANOVA/ANCOVA tests. F statistics and P value were reported based on Group source analysis.

^a Crude analysis

^b Adjusted to baseline measurement of the variable (as covariance)

^c Adjusted t baseline measurement of the variable and baseline O₂ saturation (free air) (as covariance)

Table 3 presents all of the SF-36 domains and summary scores after one month and three

287 months. All scores were higher in the PPT group than the basic care group, except body pain

after one month and role limitation due to physical health, mental health, and mental component

- summary score after three months. Only the differences in body pain domain score reach a
- 290 statistically significant level.

Table3. Distribution of SF-36 domains according to two arms in addition to related effect sizes after one and three months.

SF-36	Time	Groups		- F (P-value)**	MD [95 % CI]	SMD [95 %	Partial	
Domain	Time	PPT*	Basic care [*]	- F (P-value) MD [95 % C1]		CI]	eta ²	
PF	one-month ^a	41.7 ± 24.9	35.1 ± 23.1	.5 (.49)	6.53 [-12.44, 25.5]	.27 [48, 1.02]	.018	
PF	three-month ^b	45.8 ± 18.6	43.3 ± 18.4	.11 (.74)	2.5 [-12.91, 17.91]	.13 [66, .92]	.005	
RP	one-month	40.6 ± 44.6	18.7 ± 33.9	2.01 (.17)	21.87 [-9.86, 53.61]	.54 [23, 1.3]	.072	
KP	three-month	54.7 ± 33.2	62.5 ± 35.8	.32 (.58)	-7.81 [-36.27, 20.65]	23 [-1.02, .57]	.013	
BP	one-month	62.5 ± 31.4	69.4 ± 30.1	.35 (.56)	-6.94 [-31.13, 17.25]	22 [97, .53]	.013	
ВР	three-month	77.1 ± 20.1	54.4 ± 22.5	6.82 (.01)	22.64 [4.75, 40.52]	1.05 [.2, 1.89]	.221	
CU	one-month	67.5 ± 28.8	60 ± 21.2	.58 (.45)	7.5 [-12.81, 27.81]	.29 [46, 1.04]	.021	
GH	three-month	68.1 ± 23.2	61.5 ± 31.2	.38 (.54)	6.62 [-15.42, 28.67]	.25 [55, 1.04]	.016	
VT	one-month	55.9 ± 32.3	55 ± 18.7	.01 (.93)	.93 [-20.57, 22.44]	.03 [71, .78]	.000	
V I	three-month	58.1 ± 20.6	57.5 ± 29.8	.00 (.95)	.62 [-20.97, 19.72]	.02 [76, .81]	.000	
SF	one-month	71.9 ± 30.4	57.3 ± 29.9	1.6 (.22)	14.59 [-9.13, 38.3]	.48 [28, 1.24]	.057	
SF	three-month	76.6 ± 20.8	66.2 ± 27	1.2 (.28)	10.31 [-9.12, 29.75]	.44 [36, 1.24]	.046	
DE	one-month	68.7 ± 41.2	58.3 ± 45.2	.4 (.53)	10.42 [-23.31, 44.14]	.24 [51, .99]	.015	
RE	three-month	75 ± 39.44	73.3 ± 43.9	.01 (.92)	1.67 [-32.58, 35.91]	.04 [75, .83]	.000	
MII	one-month	71.5 ± 26.3	68 ± 21.7	.14 (.71)	3.5 [-15.7, 22.7]	.14 [61, .89]	.005	
MH	three-month	64 ± 16.2	67.6 ± 17.3	.29 (.6)	-3.6 [-17.44, 10.24]	22 [-1.01, .58]	.012	
MCSS	one-month	51.4 ± 14.5	48.5 ± 16.3	.23 (.63)	2.82 [-14.81, 9.17]	.18 [57, .93]	.008	
MCSS	three-month	50 ± 10.4	50.1 ± 15	.00 (.98)	13 [-10.41, 10.14]	.01 [8, .78]	.000	
DCSC	one-month	37.5 ± 10.5	34.3 ± 12.2	.56 (.46)	3.24 [-5.62, 12.1]	.29 [47, 1.04]	.021	
PCSS	three-month	42.2 ± 10.3	38.9 ± 10.3	.6 (.44)	3.21 [-5.33, 11.76]	.31 [48, 1.1]	.024	

PF: Physical functioning; RP: Role limitations due to physical health; BP: Body pain; GH: General health; VT: Vitality; SF: Social functioning; RE: Role limitation due to emotional problems; MH: Mental health; MCSS: Mental component summary score; PCSS: Physical component summary score; PPT: Pulmonary physiotherapy; SF-36: Short form-36; Mean difference; SMD: Standardized mean difference (based on Cohen's d test); CI: Confidence interval.

*Expressed as mean \pm standard deviation.

** Analyzed using ANOVA tests.

^a 16 and 12 patients participated to assessment of quality of life after one month in PPT and basic care groups, respectively.

^b 16 and 10 patients participated to assessment of quality of life after three months in PPT and basic care groups, respectively.

291

292 During one month after end of the intervention, two and six participants in the PPT group and

basic care group were died (OR=.26 [.04, 1.49], P=.13, table 4). After considering baseline Spo2

as a covariate, OR was reduced (OR=.19 [.03, 1.30], P=.09). After three months, all allocated

295 participants to PPT group were survived and one patient in basic care group was died (crude

analysis: OR=.21 [.04, 1.16], P=.073; after considering baseline Spo2 as a covariate: OR=.16 296

297 [.26, 1.05], P=.056; table 4).

Table 4. The mortality rate	Allocated group	Mortality +	Mortality -	Odds ratio [95% CI]	Risk difference [95% CI]	Risk ratio [95% CI]
	PPT group	2 (10%)	18 (90%)	.26	2 [44, .04]	.33
	Basic care group	6 (30%)	14 (70%)	[.04, 1.49]		[.08, 1.46]
Three-month mortality	PPT group	2 (10%)	18 (90%)	.21 [.04, 1.16]	25 [5,00]	.29 [.07, 1.21]
	Basic care group	7 (35%)	14 (65%)			

ble 4 Th J J 24 alatad affaat a

PPT: Pulmonary physiotherapy; CI: Confidence interval

298 No related adverse events were observed during the intervention period. The physiotherapists

299 reported a minimal Spo2 decrease and minimal hemodynamic instability in some patients during

300 PPT that was resolved a few minutes after the session. Also, the data monitoring committee

301 confirmed that the reason for one case intubation in the experimental group during three days

seems to not be related to the PPT. 302

Discussion 303

According to our knowledge, this study is the first RCT to evaluate the efficacy of the PPT 304

305 through comparison with a control group on non-intubated hospitalized patients with severe COVID-19 pneumonia. Our designed interventions seem to be safe and effective without serious 306

307 adverse effects.

In general, the results show that participants' pO2, PH, 3MWT, and level of dyspnea values were 308

309 improved in the PPT group than the basic care group after adjustment of each measurement to

the baseline measure. Spo2 was also higher in the PPT group than the basic care group clinically 310

- 311 significant after three days [30]. Based on the result of standardized mean differences, PPT
- decreased pCO2 with a small effect size (NNT \approx 6) and improved pO2 (NNT \approx 2), venous blood 312
- 313 PH (NNT= 2), level of dyspnea (NNT \approx 2), and RPE after walking (NNT \approx 2) with a large effect
- size, but inconclusive. PPT also improved Spo2 (NNT \approx 2) and distance of 3MWT (NNT \approx 2) 314
- 315 with a very large effect size, but inconclusive. The NNT analyzes showed that it seems one

316 patient with severe COVID-19 pneumonia can benefit from the PPT regarding Spo2, VBG 317 analysis, functional capacity, and dyspnea measures if it is applied to at least two patients. 318 After one-month follow-up, PPT was associated with higher HRQOL in role limitation due to physical health domain (NNT \approx 3) with a moderate effect size. Also, patients in PPT group 319 320 presented higher score in body pain domain of SF-36 instrument than basic care group (NNT \approx 2) after three months with a large effect size. Patients with COVID-19 suffer from significant 321 322 physical and psychological impairments that impact their HRQOL; Therefore, interventions improving HRQOL like rehabilitation should be considered in their management [36]. Although 323 some limited domains of SF-36 presented higher value in the PPT group than the control group 324 at one-month and three-month with very small effect size, but higher values of other domains in 325 the PPT group than control group can suggest that prolonged duration rehabilitation, especially 326 after discharge, may improve physical and psychological impairments and HROOL. It has been 327 shown that six weeks of respiratory rehabilitation could improve respiratory function, aerobic 328 capacity, HROOL, and anxiety of elderly patients with COVID-19, as reported by Liu and 329 colleagues [14]. 330

331 Allocated participants to the PPT group had a 20% and 25% lower one-month and three-month mortality rate than the basic care group, respectively. The NNT analysis shows that PPT kept 332 alive one out of five patients until one month. However, the results of logistic test of one-month 333 334 mortality rate is not statistically significant. Based on the NNT analysis, PPT can keep alive one 335 out of four patients until three months. A similar finding was reported in patients after lobectomy after lung cancer by Çınar et al. (2020). They showed that patient received postoperative 336 337 respiratory physiotherapy had no mortality after 30 days, while patients received standard postoperative care had 8% 30-day mortality rate [37]. In a systematic review and meta-analysis, 338 339 Ryrsø et al. (2018) reported that supervised, early pulmonary rehabilitation could be associated to statistically significant mortality reduction (RR .58 [95% CI .34, .98]) in patients with acute 340 341 exacerbation of chronic obstructive pulmonary disease compared to usual post-exacerbation care or no pulmonary rehabilitation program [38]. 342

Adjusting each variable to its baseline measurement increased partial eta2>10% than crude

analysis, suggesting that even small differences of each measured outcome can change the

results. A similar effect was not found about baseline Spo2.

346 There are currently some published studies with different levels of evidence, mostly review of 347 investigations about PPT and other cases of viral pneumonia such as influenza, expert opinions, 348 and consensus statements recommended how and when to use PPT for patients with different stages of COVID-19 pneumonia. Some researchers, physiotherapy, and rehabilitation experts 349 350 have recommended PPT as an effective rehabilitative intervention for patients with all stages of 351 COVID-19 pneumonia [4, 7, 11, 12]. Other researchers believed that only ACT should be 352 applied in the presence of EPS to patients with the severe stage under special conditions; However, they have not suggested utilizing other PPT techniques like diaphragmatic breathing, 353 354 respiratory muscle training, incentive spirometers, manual mobilization, and exercise training [1, 8, 9, 13]. They explained that acute patients often have a shallow and rapid respiratory pattern 355 356 that has been adapted spontaneously to make the minimal effort; therefore, any change in this 357 strategy may harm the patient. No other reason was given for considering PPT contraindicated in 358 the severe stage of COVID-19 pneumonia [10]. We observed some of these events like Spo2 359 decreasing and cough stimulating, but all were resolved just some minutes after the session. In our clinical setting, we also sometimes observed that Spo2 decreases during breathing through 360 361 continuous positive airway pressure, while using this non-invasive ventilator is recommended [39]. Our results showed that PPT seems not to be a contraindication for severe stage COVID-362 363 19, but it also may help therapeutic procedures.

364 About 34% of patients with COVID-19 pneumonia suffer from EPS [3]; therefore, ACT can be 365 an effective treatment for them [14]. On the other hand, the main cell target of SARS-Cov-2 is type II pneumocyte, which is responsible for pulmonary surfactant synthesis [40]. As the 366 367 pulmonary surfactant increases pulmonary compliance and facilitates the recruitment of collapsed airways [41], SARS-Cov-2 may cause alveolar stiffness. As there are some time-368 369 dependent properties of the tissue like creep and stress relaxation, a possible reason for the rationality of breathing exercises in the early phase can be their roles in tissue stiffness reduction 370 371 or prevent pneumonia progression. Based on this hypothesis, early PPT in the acute phase may 372 have therapeutic, preventive, and rehabilitative roles in the management of COVID-19 373 pneumonia. We did not have any assessment of lung tissue stiffness; therefore, our results support this possible hypothesis indirectly. Future researches with radiologic assessments that 374 show tissue characteristics like chest computed tomography scan can test this hypothesis to some 375 376 extent.

377 Our used PPT program had three main characteristics. First, choose the type of PPT technique(s) 378 based on the patients' signs and symptoms. We used IHT with emphasis on diaphragmatic 379 breathing and educated them on how to cough and breathe properly, but ACTs were only applied to patients with EPS signs and symptoms. Second, we also defined some criteria for holding the 380 381 intervention to get better safety. Third, we set a mild aerobic exercise in addition to chest physiotherapy to prevent muscle wasting and aerobic deterioration, which are seen in patients 382 383 with COVID-19 [4]. We highly recommend that patients take a sufficient dose of oxygen and be under accurate monitoring during exercises. 384

Our research had some limitations which should be considered in future studies. First, we 385 selected the sample size as MCID of Spo2 as the primary outcome measurement, but this number 386 seems to have not enough power for other variables. For example, allocated participants in the 387 PPT group had a 20% lower mortality rate than the control group. This RD seems to be 388 389 influential; however, the results of logistic tests in the mortality rate did not reach a statistically 390 significant level. Therefore, further investigations with a larger sample size are highly suggested evaluating safety and efficacy of PPT in patients with COVID-19. Second, we only recruited 391 392 participants from a single center. Now, different centers have particular therapeutic guidelines that can impact the results of PPT. The applied interventions in this study with three-day 393 duration, no need for specific tools and, low risk of adverse events suggest the feasibility of 394 395 multi-center investigations on PPT effectiveness and safety on hospitalized patients with 396 COVID-19. Third, we only recruited patients with a severe stage of COVID-19. Based on the mentioned possible mechanism, PPT may be more effective if to be started before disease 397 398 severity reaches to severe phase even when the symptoms appear; therefore, future researchers are recommended to investigate the efficacy of PPT in patients with mild and moderate stages of 399 400 COVID-19. Fourth, as participants of this study were from different cities, we could not reassess their respiratory functions, aerobic capacity, and level of dyspnea. It is highly 401 402 recommended that future researchers follow the objective pulmonary functions up to after patients' discharge after applying PPT during the hospital stay. 403

404 **Conclusion**

The results of this RCT suggest early PPT during three days, including airway clearance
 techniques, in the presence of excessive pulmonary secretion, and inspiratory hold breathing with

407 emphasis to diaphragmatic breathing for hospitalized adult patients with a severe stage of

408 COVID-19 pneumonia. Despite some recommendation, PPT seems to be safe and effective in

- the management of patients with severe COVID-19. The impact of early PPT on the mortality
- 410 rate of these patients is currently indeterminate. Further researches with larger sample size are
- 411 needed to evaluate the efficacy of PPT on COVID-19 patients with different severity stages.

412 **Contribution**

- 413 MJ, AS, AK, MTB, ND, and BAM made substantial contributions to the conception and
- designed the study. MJ, ND, and SA contributed to applying the intervention or acquisition of
- the data. MJ and AK analysed the data. AK was responsible for the statistical analysis. BAM was
- responsible for data safety monitoring during the study. MJ, ND, and BAM interpreted the data
- and drafted the manuscript. MJ and BAM verified the data. All authors had access to the data,
- 418 revised the manuscript, and approved it.

419 **Declaration of interests**

420 The authors declare no competing interests.

421 Data sharing

All individual participant data that underline the results reported in this article, after deidentification (text, tables, figures, and appendices), statistical analysis plan and Informed consent form are available from the corresponding author and Mohammad Javaherian (Email: Javaherian_m@razi.tums.ac.ir) for researchers who provide a related approved proposal and ethical committee approve to achieve aims. Patient-level information will be anonymised and study documents will be redacted to protect the privacy of trial patients. These data will be available with publication date until one year.

429 Acknowledgment

430 The researchers sincerely thank all physicians and nurses of intermediate care wards of IKHC.

431 The authors would like to appreciate the methodologist's support and constructive comments (s)

432 research development office, IKHC, Tehran, Iran.

433 **References**

Andrade AdN, Nepomuceno B, Xavier DS, Lima E, Gonzalez I, Santos JC, et al. Evidence-based
 Physiotherapy and Functionality in Adult and Pediatric patients with COVID-19. J Hum Growth Dev.
 2020;30(1):148-55.

4372.Organization WH. Coronavirus Disease (COVID-19): Weekly Epidemiological Update (27 July4382021).https://www.who.int/publications/m/item/weekly-epidemiological-update---19-january-4392021

440 3. Organization WH. COVID-19 clinical management: living guidance, 25 January 2021. World 441 Health Organization, 2021.

442 4. Wang TJ, Chau B, Lui M, Lam G-T, Lin N, Humbert S. Physical medicine and rehabilitation and 443 pulmonary rehabilitation for COVID-19. Am J Phys Med Rehabil. 2020;99(9):769-74.

444 5. Ntoumenopoulos G, Presneill J, McElholum M, Cade J. Chest physiotherapy for the prevention of 445 ventilator-associated pneumonia. Intensive Care Med. 2002;28(7):850-6.

446 6. Ciesla ND. Chest physical therapy for patients in the intensive care unit. Phys. Ther. 447 1996;76(6):609-25.

4487.Aytür YK, Köseoğlu BF, Taşkıran ÖÖ, Ordu-Gökkaya NK, Delialioğlu SÜ, Tur BS, et al. Pulmonary449rehabilitation principles in SARS-COV-2 infection (COVID-19): A guideline for the acute and subacute450rehabilitation. Turk J Phys Med Rehabil. 2020;66(2):104.

Vitacca M, Carone M, Clini EM, Paneroni M, Lazzeri M, Lanza A, et al. Joint statement on the role
of respiratory rehabilitation in the COVID-19 crisis: The Italian position paper. Respiration. 2020 May 19.
doi: 10.1159/000508399.

454 9. Thomas P, Baldwin C, Bissett B, Boden I, Gosselink R, Granger CL, et al. Physiotherapy 455 management for COVID-19 in the acute hospital setting: clinical practice recommendations. J 456 Physiother. 2020; 66: 73-82.

Lazzeri M, Lanza A, Bellini R, Bellofiore A, Cecchetto S, Colombo A, et al. Respiratory
physiotherapy in patients with COVID-19 infection in acute setting: a Position Paper of the Italian
Association of Respiratory Physiotherapists (ARIR). Monaldi Arch Chest Dis. 2020 March 25. doi:
10.4081/monaldi.2020.1285

Liebl ME, Gutenbrunner C, Glaesener JJ. Early rehabilitation in COVID-19–best practice
recommendations for the early rehabilitation of COVID-19 patients. PHYS MED REHAB KUROR. 2020
May 5. doi: 10.1055/a-1162-4919.

464 12. Zeng B, Chen D, Qiu Z, Zhang M, Wang G, Wang J, et al. Expert consensus on protocol of
465 rehabilitation for COVID-19 patients using framework and approaches of WHO International Family
466 Classifications. Aging Med. 2020 July 6; doi: 10.1002/agm2.12120.

467 13. Yang LL, Yang T. Pulmonary rehabilitation for patients with coronavirus disease 2019 (COVID468 19). Chronic Dis Transl Med. 2020 May 14. doi: 10.1016/j.cdtm.2020.05.002.

Liu K, Zhang W, Yang Y, Zhang J, Li Y, Chen Y. Respiratory rehabilitation in elderly patients with
COVID-19: A randomized controlled study. Complement Ther Clin Pract. 2020 April 1. doi:
10.1016/j.ctcp.2020.101166.

15. Nydahl P, Sricharoenchai T, Chandra S, Kundt FS, Huang M, Fischill M, et al. Safety of patient
mobilization and rehabilitation in the intensive care unit. Systematic review with meta-analysis. ATS.
2017;14(5):766-77.

475 16. Goñi-Viguria R, Yoldi-Arzoz E, Casajús-Sola L, Aquerreta-Larraya T, Fernández-Sangil P, Guzmán-476 Unamuno E, et al. Respiratory physiotherapy in intensive care unit: Bibliographic review. Enferm.

477 Intensiva (English ed). 2018;29(4):168-81.

478 17. Anekwe DE, Biswas S, Bussières A, Spahija J. Early rehabilitation reduces the likelihood of
479 developing intensive care unit-acquired weakness: a systematic review and meta-analysis.
480 Physiotherapy. 2020;107:1-10.

481 18. Stiller K. Physiotherapy in intensive care: an updated systematic review. Chest. 2013;144(3):825482 47.

483 19. Efird J. Blocked randomization with randomly selected block sizes. Int. J. Environ. Res. Public
484 Health. 2011;8(1):15-20.

485 20. Theodore AC, Manaker S, Finlay G. Venous blood gases and other alternatives to arterial blood 486 gases. 2019; https://www.uptodate.com/contents/venous-blood-gases-and-other-alternatives-to-487 arterial-blood-gases (accessed January 23)..

488 21. Louw A, Cracco C, Cerf C, Harf A, Duvaldestin P, Lemaire F, et al. Accuracy of pulse oximetry in 489 the intensive care unit. Intensive Care Med. 2001; 27: 1606-1613.

Yaqoob I, Quddus N, Farooq A, Zafar M, Ghous M. Comparison of the impact of six minute walk
test with three minute step test on vitals in healthy young individuals for measuring functional
endurance. RMJ. 2019;44(3):490-3.

493 23. Robertson RJ, Goss FL, Metz KF. Perception of physical exertion during dynamic exercise: a 494 tribute to Professor Gunnar AV Borg. Percept Mot Skills. 1998;86(1):183-91.

49524.Gift AG. Validation of a vertical visual analogue scale as a measure of clinical dyspnea. Rehabil496Nurs. 1989; 14: 323-325.

49725.Ander DS, Aisiku IP, Ratcliff JJ, Todd KH, Gotsch K. Measuring the dyspnea of decompensated498heart failure with a visual analog scale: how much improvement is meaningful? CHF. 2004;10(4):188-91.

49926.DeputyofTreatmentMoHaME.PatientClinicalPathwayCOVID-19.2020.500http://treatment.sbmu.ac.ir/uploads/1-9-Patient_Clinical_Pathway_COVID_19.pdf

50127.Hillegass E. Essentials of Cardiopulmonary Physical Therapy: fourth edition. Missouri: Elsevier502Health Sciences, 2016.

503 28. Wilson RC, Jones P. A comparison of the visual analogue scale and modified Borg scale for the 504 measurement of dyspnoea during exercise. Clin. Sci. 1989;76(3):277-82.

50529.Montazeri A, Goshtasebi A, Vahdaninia M, Gandek B. The Short Form Health Survey (SF-36):506translation and validation study of the Iranian version. Qual Life Res. 2005; 14: 875-882..

50730.Tobin MJ, Laghi F, Jubran A. Why COVID-19 silent hypoxemia is baffling to physicians. Am J508Respir Crit Care Med. 2020; 202: 356-360.

509 31. Altschul DJ, Unda SR, Benton J, de la Garza Ramos R, Cezayirli P, Mehler M, et al. A novel 510 severity score to predict inpatient mortality in COVID-19 patients. Sci Rep. 2020 October 7. doi: 511 10.1038/s41598-020-73962-9.

512 32. Vickers AJ. The use of percentage change from baseline as an outcome in a controlled trial is 513 statistically inefficient: a simulation study. BMC Med Res Methodol. 2001; 1: 1-6.

514 33. De Boer MR, Waterlander WE, Kuijper LD, Steenhuis IH, Twisk JW. Testing for baseline 515 differences in randomized controlled trials: an unhealthy research behavior that is hard to eradicate. Int 516 J Behav Nutr Phys Act. 2015 Dec 12. doi: 10.1186/s12966-015-0162-z.

517 34. Imbens GW, Rubin DB. Causal inference in statistics, social, and biomedical sciences. New York: 518 Cambridge University Press; 2015.

519 35. Furukawa TA, Leucht S. How to obtain NNT from Cohen's d: comparison of two methods. PLoS 520 one. 2011 April 27. doi: 10.1371/journal.pone.0019070.

521 36. Chen KY, Li T, Gong F, Zhang JS, Li XK. Predictors of health-related quality of life and influencing 522 factors for COVID-19 patients, a follow-up at one month. Front Psychiatry. 2020 Nov. doi: 523 10.3389/fpsyt.2020.00668.

524 37. Çınar HU, Çelik HK, Çelik B, Doğan C. Is respiratory physiotherapy effective on pulmonary 525 complications after lobectomy for lung cancer? Turk Gogus Kalp Damar Cerrahisi Derg. 2020;28(4):638.

526 38. Ryrsø CK, Godtfredsen NS, Kofod LM, Lavesen M, Mogensen L, Tobberup R, et al. Lower 527 mortality after early supervised pulmonary rehabilitation following COPD-exacerbations: a systematic 528 review and meta-analysis. BMC Pulm. Med.. 2018;18(1):1-18.

529 39. Ashish A, Unsworth A, Martindale J, Sundar R, Kavuri K, Sedda L, et al. CPAP management of

530 COVID-19 respiratory failure: a first quantitative analysis from an inpatient service evaluation. BMJ

531 Open Respir. Res. 2020;7(1). doi: 10.1136/bmjresp-2020-000692.

532 40. Franks TJ, Chong PY, Chui P, Galvin JR, Lourens RM, Reid AH, et al. Lung pathology of severe

- acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore. Hum Pathol. 2003; 34:
- 534 743-748.
- 535 41. Desai JP, Moustarah F. Pulmonary compliance. StatPearls [Internet]. 2019 Feb 18.


537 Supporting information


538 **S1 Table. The reason for protocol modifications.**

Type of Modification	Time of modification during the study	Reason(s)
Changing the "level of dyspnea" from primary to secondary outcome measurement Changing the "rating perceived of exertion after the three-minute walk test" from primary to secondary outcome measurement	Before enrollment	Their role in the sample size calculation. The role of these outcomes were not important in this research to be considered as primary outcome measurement.
Changing the "Venous Blood PH" from primary to secondary outcome measurement		
Consider the history of intubation due to COVID-19 pneumonia as exclusion criteria.	Before enrollment	 When the research team was preparing to start enrolling the participants, they found that there are cases weaned from mechanical ventilator recently. Based on defined inclusion/exclusion criteria, they could include in the study because they could consider patients with severe COVID-19. As the main aim of this study was to evaluate the efficacy and safety of pulmonary physiotherapy in the severe stage of COVID-19 to determine that can this treatment improve patients with COVID-19 and prevent their deterioration? Finally, the research team decided to consider the history of intubation due to COVID-19 as exclusion criteria.

539

The permissions of all of the modifications were taken from the ethical committee of Tehran University of MedicalSciences.





^{*} These participants were intubated during three days and therefore did not participate in the assessment after three days. They died before one-month follow-up.